Nasal steroids provided the most significant benefit, especially when compared to montelukast. Nasal antihistamines also ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

People in England with a severe dust mite allergy are set to be offered a daily pill on the NHS, it has been announced today (Thursday January 30), as part of a big shake up.

A new treatment for severe dust mite allergy has been recommended by NICE, for patients whose symptoms have not been helped ...

In CRS with and without nasal polyps, medical treatment, including nasal and oral corticosteroids, is the first therapeutic option. The treatment of CRS still remains an unmet need ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

New NHS treatment gives hope to thousands who suffer from common allergy - The first-of-its-kind tablet will offer relief ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...